Why the study?
Does bumetanide, bendroflumethiazide, and hydralazine increase urinary kallikrein excretion in normotensive and spontaneously hypertensive rats?
Does bumetanide, bendroflumethiazide, and hydralazine increase urinary kallikrein excretion in normotensive and spontaneously hypertensive rats?
Administration of bumetanide, bendroflumethiazide, and hydralazine increases urinary kallikrein excretion in rats, which may be related to increased renal blood flow.
Bumetanide, bendroflumethiazide and hydralazine may increase urinary kallikrein in rats; leaves open mechanistic and translational relevance.
Single and/or repeated administrations of bumetanide, bendroflumethiazide and hydralazine to normotensive and spontaneously hypertensive rats resulted in an increase of urinary kallikrein excretion. No correlation was found with sodium output. The role of the increased plasma renin activity is discussed and it is suggested that the activation of the renal kallikrein-kinin system is related to the increase in renal blood flow.
No takes yet. Share an insight, caveat, or question.
Nielsen et al. (1977) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: